Aspiro Pharma Specialities Private Limited - Company Profile

It is a pharma private limited company based in Gujvail, Telangana, India, established in 2020.
2020 Gujvail, Telangana, India Amalgamated
Last Updated:
Access Report
About Aspiro Pharma Specialities Private Limited

Aspiro Pharma Specialities Private Limited, a amalgamated private limited company, was established on 29 August 2020 in Gujvail, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24299TG2020PTC143320. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹55.00 Cr and a paid-up capital of ₹55.00 Cr.

It upholds a compliant status. Its leadership includes Bhavesh Bansidhar Pujara (Director), Mahesh Ramappa Kamalamma Hassan (Director). Past directors included Bhavesh Bansidhar Pujara, Sudhakar Gangula, Chandra Sekhar Tumuluru. It holds ₹25.00 Cr open charges and ₹25.00 Cr settled loans. Its latest AGM occurred on 24 July 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. S-1, S-6 & S-2B, Survey No. 321 & 284, Biotech Park Phase - Iii,, Karakapatla Vill, Markook Mandal, Siddipet Dist, Gujvail, Telangana, 502281.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24299TG2020PTC143320

  • Registration Number

    143320

  • Incorporation Date

    29 August 2020

  • Authorized Capital

    ₹55.00 Cr

  • Paid-Up Capital

    ₹55.00 Cr

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Amalgamated

Key Metrics
  • Authorised Capital ₹ 55.00 Cr
  • Paid Up Capital ₹ 55.00 Cr
  • Company Age 5 Year, 6 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 25.00 Cr
  • Satisfied Charges ₹ 25.00 Cr
  • Revenue Growth **** 312.79%
  • Profit Growth **** 179.46%
  • Ebitda ****
  • Net Worth 45.17%
  • Total Assets **** 169.42%
Company report

Aspiro Pharma Specialities Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Aspiro Pharma Specialities Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Aspiro Pharma Specialities Private Limited?
Current Directors
Name Designation Appointment Date Status
Bhavesh Bansidhar Pujara Director 13 Nov 2024 Current
Mahesh Ramappa Kamalamma Hassan Director 13 Nov 2024 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 23 Jul 2025 Past
Pramod Abcsdd Managing Director 13 Nov 2024 Past
Pramod Abcsdd Additional Director 23 Jul 2025 Past
Pramod Abcsdd Additional Director 23 Jul 2025 Past
Pramod Abcsdd Director 13 Nov 2024 Past
Pramod Abcsdd Company Secretary - Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Aspiro Pharma Specialities.

Sundhet Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 312.79% increase. The company also saw a substantial improvement in profitability, with a 179.46% increase in profit. The company's net worth Soared by an impressive increase of 45.17%.

Aspiro Pharma Specialities revenue growth over time
Aspiro Pharma Specialities profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 312.79%
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
 169.42%
*******
*******
*******
*******
Profit or Loss
*******
 179.46%
*******
*******
*******
*******
Net Worth
*******
 45.17%
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Aspiro Pharma Specialities?

In 2023, Aspiro Pharma Specialities had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹250,000,000.00

Satisfied Charges

₹250,000,000.00

Charges Breakdown by Lending Institutions
  • State Bank Of India : 25.00 Cr
Latest Charge Details
Date Lender Amount Status
28 Jun 2022 State Bank Of India ₹25.00 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Aspiro Pharma Specialities?

Aspiro Pharma Specialities has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Aspiro Pharma Specialities, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspiro Pharma Specialities's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Aspiro Pharma Specialities
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Aspiro Pharma Specialities Private Limited last Annual general meeting of members was held on 24 Jul 2025 as per latest MCA records. was documented.

  • Charges

    A charge registered on 28 Jun 2022 via Charge ID 100593128 with State Bank Of India was fully satisfied on 29 May 2025. was recorded as a recent event.

  • Director Appointment

    Surekha Anandrao Limbure was appointed as a Company Secretary was appointed as a Company Secretary on 25 Apr 2025 & has been associated with this company since 10 months 6 days . was recorded as a recent event.

  • Balance Sheet

    Aspiro Pharma Specialities Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was recorded as a recent event.

  • Director Appointment

    The activity Dakarapu Srinivas was appointed as a Cfo was appointed as a Cfo on 04 Feb 2025 & has been associated with this company since 1 year 25 days . was completed.

  • Director Appointment

    Bhavesh Bansidhar Pujara was appointed as a Director was appointed as a Director on 13 Nov 2024 & has been associated with this company since 1 year 3 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Aspiro Pharma Specialities Private Limited?

The CIN of Aspiro Pharma Specialities Private Limited is U24299TG2020PTC143320.

Where is Aspiro Pharma Specialities Private Limited headquartered?

Aspiro Pharma Specialities Private Limited is headquartered at Plot No. S-1, S-6 & S-2B, Survey No. 321 & 284, Biotech Park Phase - Iii,, Karakapatla Vill, Markook Mandal, Siddipet Dist, Gujvail, Telangana, 502281.

When was Aspiro Pharma Specialities Private Limited incorporated?

Aspiro Pharma Specialities Private Limited was incorporated on 29 August 2020.

Who are the current directors of Aspiro Pharma Specialities Private Limited?

The current directors of Aspiro Pharma Specialities Private Limited are

What is the primary industry of Aspiro Pharma Specialities Private Limited?

The primary industry of Aspiro Pharma Specialities Private Limited is Manufacturing.

Is Aspiro Pharma Specialities Private Limited a listed company?

Aspiro Pharma Specialities Private Limited is unlisted.

What is the capital structure of Aspiro Pharma Specialities Private Limited?

The authorized capital of Aspiro Pharma Specialities Private Limited is ₹55.00 Cr, and the paid-up capital is ₹55.00 Cr.

What is the compliance status of Aspiro Pharma Specialities Private Limited?

The compliance status of Aspiro Pharma Specialities Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available